ADVERTISEMENT

Sun Pharma - Concert Deal Paves Way To Add JAK Inhibitors To Specialty Portfolio: Motilal Oswal

Adds Deuroxolitinib, a potential best-in-class JAK inhibitor, to its specialty portfolio through acquisition of Concert Pharma Inc

<div class="paragraphs"><p>A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai. (Photo: Francis Mascarenhas/Reuters)</p></div>
A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai. (Photo: Francis Mascarenhas/Reuters)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More